P BCMACD19 ALLO1
Alternative Names: BCMA/CD19 dual-target CAR-T cell immunotherapy - Poseida Therapeutics; BCMA/CD19 dual-targeting CAR-T therapy - Poseida Therapeutics; Dual CAR-BCMA-19- Poseida Therapeutics; P-BCMACD19-ALLO1Latest Information Update: 09 Aug 2022
At a glance
- Originator Poseida Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 03 Aug 2022 Poseida Therapeutics enters into a collaboration and license agreement with Roche to develop P BCMACD19 ALLO1
- 02 Aug 2022 Poseida Therapeutics plans to submit IND application for phase I trial in Multiple myeloma
- 29 Jul 2022 P BCMACD19 ALLO1 is available for licensing as of 29 Jul 2022. https://poseida.com/